(SBIO) ALPS Medical Breakthroughs - Ratings and Ratios
Biotech, Small-Cap, Mid-Cap, Phase-II, Phase-III
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 29.6% |
| Value at Risk 5%th | 48.9% |
| Relative Tail Risk | 0.34% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.44 |
| Alpha | 35.73 |
| CAGR/Max DD | 0.43 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.400 |
| Beta | 0.895 |
| Beta Downside | 0.800 |
| Drawdowns 3y | |
|---|---|
| Max DD | 42.44% |
| Mean DD | 12.16% |
| Median DD | 10.73% |
Description: SBIO ALPS Medical Breakthroughs December 28, 2025
The ALPS Medical Breakthroughs ETF (SBIO) follows a passive indexing strategy, aiming to mirror its benchmark by allocating at least 80% of net assets to the constituent securities. The index focuses on U.S. small- and mid-cap biotechnology firms that have at least one drug candidate in FDA Phase II or Phase III clinical trials.
Key data points: SBIO’s expense ratio is approximately 0.68% and it manages roughly $500 million in assets, reflecting modest scale in a niche sector. The biotech industry is projected to grow at a compound annual growth rate of about 10% through 2029, driven by rising R&D spending and an expanding pipeline of gene-therapy and immuno-oncology products. Historically, only about 15% of Phase II candidates receive FDA approval, underscoring the high-risk, high-reward nature of the ETF’s holdings.
For a deeper dive into SBIO’s valuation metrics and risk profile, you might explore the analysis on ValueRay.
What is the price of SBIO shares?
Over the past week, the price has changed by +4.92%, over one month by +0.55%, over three months by +24.57% and over the past year by +66.46%.
Is SBIO a buy, sell or hold?
What are the forecasts/targets for the SBIO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 55.6 | 8.3% |
SBIO Fundamental Data Overview January 10, 2026
Revenue TTM = 0.0 USD
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 125.0m USD (125.0m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 125.0m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 125.0m / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 9.21% (E(125.0m)/V(125.0m) * Re(9.21%) + (debt-free company))
Discount Rate = 9.21% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)
Additional Sources for SBIO ETF
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle